Pece-Barbara N, Cymerman U, Vera S, Marchuk D A, Letarte M
Cancer and Blood Research Programme, Hospital for Sick Children and Department of Immunology, University of Toronto, 555 University Avenue, Toronto M5G 1X8, Canada.
Hum Mol Genet. 1999 Nov;8(12):2171-81. doi: 10.1093/hmg/8.12.2171.
ENDOGLIN codes for a homodimeric membrane glycoprotein that interacts with receptors for members of the TGF-beta superfamily and is the gene mutated in the autosomal dominant vascular disorder hereditary hemorrhagic telangiectasia type 1 (HHT1). We recently demonstrated that functional endoglin was expressed at half levels on human umbilical vein endothelial cells (HUVECs) and peripheral blood activated monocytes from HHT1 patients. Two types of mutant protein were previously analyzed, the product of an exon 3 skip which was expressed as a transient intracellular species and prematurely truncated proteins that were undetectable in patient samples. Here we report the analysis of four proteins resulting from point mutations, with missense codons G52V and C53R in exon 2, W149C in exon 4 and L221P in exon 5. Metabolic labeling of activated monocytes from confirmed, clinically affected patients revealed reduced expression of fully processed normal endoglin in all cases. Pulse-chase analysis with HUVECs from a newborn with the C53R substitution indicated that mutant endoglin remained intracellular as a precursor form and did not impair processing of the normal protein. Biotinylation of cell surface proteins, metabolic labeling and pulse-chase analysis revealed that none of the engineered missense mutants was significantly expressed at the surface of COS-1 transfectants. Thus, these four HHT1 missense mutations lead to transient intracellular species which cannot interfere with normal endoglin function. These data suggest that haploinsufficiency, leading to reduced levels of one of the major surface glyco-proteins of vascular endothelium, is the predominant mechanism underlying the HHT1 phenotype.
内皮糖蛋白编码一种同二聚体膜糖蛋白,该蛋白与转化生长因子-β超家族成员的受体相互作用,并且是常染色体显性血管疾病1型遗传性出血性毛细血管扩张症(HHT1)中发生突变的基因。我们最近证明,功能性内皮糖蛋白在HHT1患者的人脐静脉内皮细胞(HUVECs)和外周血活化单核细胞上以一半的水平表达。先前分析了两种类型的突变蛋白,一种是外显子3跳跃的产物,其表达为瞬时细胞内物质,另一种是在患者样本中无法检测到的过早截短的蛋白质。在这里,我们报告了对由点突变产生的四种蛋白质的分析,这些点突变在外显子2中有错义密码子G52V和C53R,外显子4中有W149C,外显子5中有L221P。对确诊的临床受累患者的活化单核细胞进行代谢标记显示,在所有情况下,完全加工的正常内皮糖蛋白的表达均降低。对具有C53R替代的新生儿的HUVECs进行脉冲追踪分析表明,突变的内皮糖蛋白以前体形式保留在细胞内,并且不影响正常蛋白质的加工。细胞表面蛋白的生物素化、代谢标记和脉冲追踪分析表明,在COS-1转染子表面,没有一种工程错义突变体有明显表达。因此,这四个HHT1错义突变导致瞬时细胞内物质,其不会干扰正常内皮糖蛋白的功能。这些数据表明,单倍体不足导致血管内皮主要表面糖蛋白之一的水平降低,是HHT1表型的主要潜在机制。